Key result
Statins were prescribed for primary prevention of cardiovascular disease in 55.7% of patients with type 2 diabetes, indicating suboptimal utilization compared to clinical guideline recommendations.
Why the study?
Clinical practice guidelines endorse statin use in type 2 diabetes to reduce cardiovascular disease, but little is known about statin utilization in Ethiopia.
What is the prescribing pattern and utilization rate of statins for primary prevention of cardiovascular disease in patients with type 2 diabetes in Ethiopia?
Observational (n=323)
No
What is the prescribing pattern and utilization rate of statins for primary prevention of cardiovascular disease in patients with type 2 diabetes in Ethiopia?
Statin utilization for primary prevention of cardiovascular disease in Ethiopian patients with type 2 diabetes is suboptimal and falls significantly below current clinical guideline recommendations.
Suboptimal statin prescribing in Ethiopian T2DM patients should not yet change practice; leaves open whether guideline targets improve outcomes amid weak evidence.
OBJECTIVE: Although most clinical practice guidelines endorsed statin use in type 2 diabetes (T2D) patients for reducing cardiovascular diseases (CVD), little is known about statin utilization in case of Ethiopia. Hence, this study was aimed to evaluate prescribing pattern of statins for primary prevention of CVD in T2D patients. A retrospective study conducted in T2D patients with the age group of 40-75 years. Prescriptions were audited for details of statin use and dose intensity. Descriptive analysis was performed using SPSS version 22.0. RESULTS: We included a total of 323 study subjects. Of those, 55.7% study subjects were found to be received statin for their primary prevention of CVD. Commonly prescribed type of statins was simvastatin (37.2%), atorvastatin (32.8%) and rosuvastatin (15.6%). Low, moderate and high intensive dose of statins were prescribed in 27.8%, 46.1%, and 26.1%, respectively. Of those subjects received statin, 60.6% had on target cholesterol level. Overall, a significant percentage of subjects did not receive their recommended statin for primary prevention of CVD which is below the guidelines' recommendation. Therefore, adherence to guidelines may help to promote the use of statins for primary prevention of CVD in T2D and advance interventions to improve statin prescribing should be considered.
No takes yet. Share an insight, caveat, or question.
Demoz et al. (2019) conducted an observational in Type 2 diabetes (n=323). Statin therapy vs. No statin therapy was evaluated on Prescription rate of statins for primary prevention of cardiovascular disease (95% CI 50.2-61.9). Statins were prescribed for primary prevention of cardiovascular disease in 55.7% of patients with type 2 diabetes, indicating suboptimal utilization compared to clinical guideline recommendations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: